Adherence to type 2 diabetes management

Khunti, Nitisha; Khunti, Nehal; Khunti, Kamlesh

doi:10.15277/bjd.2019.223

Cited by 32 publications

(28 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The aim of diabetes management is controlling hyperglycaemia to reduce the risk of progression to microvascular and macrovascular complications [51], but this study indicated that this population is failing to reach this target despite 85% being recorded as being on treatment. This is a worrying trend which is possibly due to a combination of diabetes disease progression with time, and a lack of compliance and adherence with the treatment and lifestyle changes [54,[56][57][58]. Further analysis is needed to establish adherence and compliance in the study population, as this cannot be determined from the retrospective data alone.…”

Section: Plos Onementioning

confidence: 99%

Diabetes in a TB and HIV-endemic South African population: Analysis of a virtual cohort using routine health data

et al. 2021

View full text Add to dashboard Cite

Background It is widely accepted that people living with diabetes (PLWD) are at increased risk of infectious disease, yet there is a paucity of epidemiology studies on the relationship between diabetes and infectious disease in SSA. In a region with a high burden of infectious disease, this has serious consequences for PLWD. Methods and findings Using routinely collected longitudinal health data, we describe the epidemiology of diabetes in a large virtual cohort of PLWD who have a high burden of HIV and TB, from the Khayelitsha subdistrict in the Western Cape Province in South Africa. We described the relationship between previous TB, newly diagnosed TB disease and HIV infection on diabetes using HbA1c results as an outcome measure. The study population was predominately female (67%), 13% had a history of active TB disease and 18% were HIV positive. The HIV positive group had diabetes ascertained at a significantly younger age (46 years c.f. 53 years respectively, p<0.001) and in general had increased HbA1c values over time after their HIV diagnosis, when compared to the HIV-negative group. There was no evidence of TB disease influencing the trajectory of glycaemic control in the long term, but diabetes patients who developed active TB had higher mortality than those without TB (12.4% vs 6.7% p-value < 0.001). HIV and diabetes are both chronic diseases whose long-term management includes drug therapy, however, only 52.8% of the study population with an HIV-diabetes comorbidity had a record of diabetes treatment. In addition, the data suggest overall poor glycaemic control in the study population with only 24.5% of the participants having an HbA1c <7% at baseline despite 85% of the study population being on diabetes treatment. Conclusion The epidemiologic findings in this exploratory study highlight the need for further research into diabetes outcomes in a high TB and HIV burden setting and demonstrate that routine health data are a valuable resource for understanding disease epidemiology in the general population.

show abstract

Section: Plos Onementioning

confidence: 99%

Diabetes in a TB and HIV-endemic South African population: Analysis of a virtual cohort using routine health data

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Allowing beneficiaries to choose their insulin-delivery method, in collaboration with their health care provider, is critical to supporting treatment satisfaction, a major driver of treatment adherence and subsequent outcomes. [103][104][105][106][107][108][109][110] The added safety of insulin pumps with predictive low glucose suspend or automated insulin delivery used in conjunction with CGM should be a strong consideration for insulin pump use by Medicare beneficiaries. Patient choice matters.…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that low treatment satisfaction is associated with poor medication adherence. 106 , 107 For individuals with insulin-treated diabetes, nonadherence to insulin treatment is often because of the pain and fear associated with injections. 108–110 As reported by Rubin et al, the prevalence of fear of injections in individuals with insulin-treated diabetes ranges from 10% to 26%.…”

Section: Medication Adherence Impacts Clinical Outcomes and Health Care Costsmentioning

confidence: 99%

Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion

Parkin¹,

Carlson

Galindo

et al. 2021

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Numerous studies have demonstrated the clinical value and safety of insulin pump therapy in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for insulin pump coverage required by the Centers for Medicare & Medicaid Services (CMS) discount conclusive evidence that supports insulin pump use in diabetes populations that are currently deemed ineligible. This article discusses the limitations and inconsistencies of the insulin pump eligibility criteria relative to current scientific evidence and proposes workable solutions to address this issue and improve the safety and care of all individuals with diabetes.

show abstract

“…Комбинация иДПП-4 и метформина является эффективной, рациональной, хорошо изученной комбинацией. Существенным преимуществом фиксированной комбинации Галвус Мет является повышение приверженности пациентов к фармакотерапии [14,[18][19][20]. Вилдаглиптин и метформин являются лекарственными средствами с доказанной эффективностью и безопасностью и обеспечивают сахароснижающий эффект за счет разнонаправленного действия на патогенетические механизмы развития СД2 [20][21][22].…”

Section: комбинация идпп-4 и метформинаunclassified

Type 2 diabetes: evidence-based medicine approach to glucose-lowering therapy

2021

View full text Add to dashboard Cite

Type 2 diabetes mellitus is a serious medical and social problem. The danger of the disease is associated with epidemic growth rates and chronic complications, leading to early disability, decreased quality of life and mortality. The prevention of diabetes complications is based on the optimal glucose-lowering therapy with the achievement of target metabolic parameters from the date the diagnosis of T2DM was established and throughout the patient’s life. The complex pathogenetic mechanisms of T2DM are the underlying rationale for drug therapy with a simultaneous effect on various disorders, which will provide a greater hypoglycemic potential and maintain effective glycemic control as T2DM progresses. The main reasons for poor disease control include clinical inertia, untimely intensification of drug therapy, and the use of treatment regimens that are insufficiently effective given the progressive course of the disease. The therapy for T2DM is based on clinical guidelines. The pathogenetic therapy options associated with the use of vildagliptin and metformin are considered. Much attention in modern diabetology is paid to the study of the influence of various therapeutic approaches on the disease progression rates from the perspective of improving prognosis and long-term maintenance of target glycemic control. The advantages of combined glucose-lowering therapy at the onset of T2DM are considered in comparison with the stepwise intensification of glucose-lowering therapy. The VERIFY study examined the long-term efficacy and safety of two treatment approaches: early vildagliptin and metformin combination therapy versus the traditional stepwise approach starting with metformin as initial therapy. The combined glucose-lowering therapy is an important direction in the treatment of patients with newly diagnosed type 2 diabetes.

show abstract

Adherence to type 2 diabetes management

Cited by 32 publications

References 43 publications

Diabetes in a TB and HIV-endemic South African population: Analysis of a virtual cohort using routine health data

Diabetes in a TB and HIV-endemic South African population: Analysis of a virtual cohort using routine health data

Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion

Type 2 diabetes: evidence-based medicine approach to glucose-lowering therapy

Contact Info

Product

Resources

About